Dazela

# Dazela ## Overview - **Classification**: Novel Oxazolidinone Antibiotic - **Mechanism**: Inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S bacterial ribosomal subunit, preventing initiation of protein synthesis. ## Primary Indications 1. **Complicated Skin and Skin Structure Infections (cSSSI)** - Including infections due to Methicillin-resistant Staphylococcus aureus (MRSA). 2. **Hospital-Acquired Pneumonia (HAP)** - Including Ventilator-Associated Pneumonia (VAP) caused by susceptible Gram-positive bacteria. 3. **Vancomycin-resistant Enterococcus faecium (VRE) Infections** - Including bacteremia. ## Adult Dosing ### Standard Dosing **Complicated Skin and Skin Structure Infections (cSSSI)** - **Dose**: **600 mg** - **Frequency**: Every **12 hours** - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: **10 to 14 days** **Hospital-Acquired Pneumonia (HAP) / VAP** - **Dose**: **600 mg** - **Frequency**: Every **12 hours** - **Route**: Intravenous (IV) - **Duration**: **10 to 14 days** **Vancomycin-resistant Enterococcus faecium (VRE) Infections** - **Dose**: **600 mg** - **Frequency**: Every **12 hours** - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: **14 to 28 days** (depending on site/severity) ### Dose Adjustments - **Renal Impairment**: No dose adjustment needed for any degree of renal impairment, including ESRD or dialysis. - **Hepatic Impairment**: No dose adjustment needed for mild to moderate hepatic impairment. Use with caution in severe impairment; monitor for adverse effects. - **Elderly Patients**: No specific dose adjustment required based on age alone. Monitor for age-related decline in renal/hepatic function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **10 mg/kg** - **Frequency**: Every **12 hours** - **Maximum**: **10 mg/kg/dose** - **Special Notes**: Use IV formulation. Monitor plasma concentrations if available, due to variable clearance. ### Infants (1-12 months) - **Dose**: **10 mg/kg** - **Frequency**: Every **8 hours** - **Maximum**: **600 mg/dose** - **Special Notes**: Oral suspension preferred for ease of administration. ### Children (1-12 years) - **Dose**: **10 mg/kg** - **Frequency**: Every **8 hours** - **Maximum**: **600 mg/dose** - **Special Notes**: Transition to oral tablets/suspension as appropriate. ### Adolescents (13-18 years) - **Dose**: Follow **adult dosing** guidelines. - **Frequency**: Every **12 hours** - **Maximum**: **600 mg/dose** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to dazela or any component. - **Absolute**: Concomitant use of MAOIs (phenelzine, isocarboxazid, tranylcypromine, selegiline) or within 2 weeks of discontinuing an MAOI. - **Relative**: Uncontrolled hypertension, pheochromocytoma, carcinoid syndrome. ### Common Adverse Effects - **Very Common (>10%)**: Headache, Nausea, Diarrhea - **Common (1-10%)**: Vomiting, Abdominal pain, Dizziness, Rash, Taste perversion, Thrush - **Serious but Rare**: Myelosuppression (thrombocytopenia, anemia, leukopenia), Peripheral neuropathy, Optic neuropathy, Serotonin syndrome. ### Key Drug Interactions - **Monoamine Oxidase Inhibitors (MAOIs)**: Risk of **hypertensive crisis**. **Contraindicated**. - **Serotonergic Drugs (SSRIs, SNRIs, TCAs)**: Risk of **serotonin syndrome**. Avoid concomitant use; if unavoidable, monitor closely for hyperthermia, rigidity, mental status changes. - **Tyramine-rich Foods/Beverages**: Risk of **hypertensive reaction**. Advise patients to limit intake. - **Myelosuppressive Agents**: Increased risk of **bone marrow suppression**. Monitor CBC closely. ## Monitoring & Follow-up - **Before Treatment**: Obtain Baseline CBC with platelets, LFTs, Renal function (CrCl). - **During Treatment**: Monitor **CBC with platelets weekly**, especially if treatment extends beyond **10 days**. - **Clinical Signs**: Monitor for signs of peripheral neuropathy (numbness, tingling), optic neuropathy (blurred vision, vision loss), and serotonin syndrome. ## Clinical Pearls - 💡 **Tip 1**: Dazela has strong activity against **MRSA** and **VRE**, making it a crucial option for resistant Gram-positive infections. - 💡 **Tip 2**: For patients on long-term therapy (>28 days), emphasize reporting any changes in **vision** or **tingling/numbness** in extremities. - 💡 **Tip 3**: Counsel patients to avoid large amounts of **tyramine-containing foods** (aged cheese, cured meats, red wine) due to potential for hypertensive reactions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.